Stockscreener 앱 받기
1.43
23.94%
-0.45
Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스
VYNE stock touches 52-week low at $1.38 amid market challenges - Investing.com
After A -27.64% Drop In Share Price, Is VYNE Therapeutics Inc (NASDAQ:VYNE) A Better Trade Than Others? - Marketing Sentinel
VYNE Therapeutics Inc (VYNE) Stock: A Year of Highs and Lows in the Market - investchronicle.com
VYNE stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
VYNE Therapeutics Provides Update on VYN202 Program | VYNE Stock News - GuruFocus
VYNE’s earnings forecast for the current quarter - uspostnews.com
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga
VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down. - Nasdaq
FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis - Dermatology Times
VYNE Therapeutics (VYNE) Target Price Cut Following FDA Clinical - GuruFocus
VYNE Therapeutics (VYNE) Faces FDA Clinical Hold on Psoriasis Dr - GuruFocus
With 36.89% Distance From Low, Could Vs Media Holdings Ltd (NASDAQ:VSME) Post Further Gains? - Marketing Sentinel
Pre-market Movers: OMEX, SES, VYNE, OLB, LEXX… - RTTNews
VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell - marketscreener.com
VYNE Therapeutics Provides Update on VYN202 Program - The Manila Times
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.1% – Here’s What Happened - Defense World
Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Yahoo Finance
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN
Invesco Canada announces cash distributions for its ETFs - The Globe and Mail
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan
New Research Confirms Effective Therapy for Nail Psoriasis - Dermatology Times
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World
VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com
VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World
HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times
Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan
VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq
Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times
Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan
VYNE begins trial for new psoriasis treatment - Investing.com
VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia
Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World
0.24%
36.06%
자본화:
|
볼륨(24시간):